Andrew Zolopa
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Infectious Diseases
Contact Information
-
Clinical Offices
Positive Care Clinic 3801 Miranda Ave Bldg MB3 Ste 350 MC 5549 Palo Alto, CA 94304 Tel Work (650) 354-8101 Fax (650) 354-8102
Professional Snapshot
Clinical Focus
- Infectious Disease
- Infectious Diseases
Professional Education
| Fellowship: | SUMC - Graduate Medical Education, CA (1992) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1988) |
| Residency: | Santa Clara Valley Medical Center, CA USA (1988) |
| Internship: | Santa Clara Valley Medical Center, CA USA (1985) |
| Medical Education: | UCLA School of Medicine, CA (1984) |
Postdoctoral Advisees
Scientific Focus
Research Interests
Dr. Zolopa’s research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohort and trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy in urban poor communities of San Francisco.
Clinical Trials
- ACTG 5128 Consent for Use of Stored Patient Specimens for Future Testing Recruiting
- ACTG 5001: Long-Term Data Collection From Participants in Adult AIDS Clinical Trials Recruiting
- A5262: A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects Recruiting
- ACTG 5240: Phase 2 study of HPV vaccine in HIV-1 Infected Females Recruiting
- ACTG 5241: The Optimized Treatment that includes or Omits NRTIs (OPTIONS) Trial Recruiting
Publications
- Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Curr HIV/AIDS Rep. 2009; (2): 63-7
- Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin Infect Dis. 2009; (5): 680-2
- Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009; (3): 290-3
- Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; (5): e5575
- Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother. 2009; (11): 4869-78
Help